Skip to main content
. 2022 Dec 8;25(2):425–432. doi: 10.1093/europace/euac225

Table 4.

First-reached endpoint at 1- and 5-year follow ups

BMI Total
1 year
Amiodarone/dronedarone, n (%) 738 (8)
Flecainid/propafenone, n (%) 395 (4)
AF hospitalization, n (%) 1903 (21)
DC conversion, n (%) 634 (7)
AF re-ablation, n (%) 251 (3)
5 year
Amiodarone/dronedarone, n (%) 771 (8)
Flecainid/propafenone, n (%) 418 (5)
AF hospitalization, n (%) 2715 (30)
DC conversion, n (%) 864 (9)
AF re-ablation, n (%) 325 (4)

AF, atrial fibrillation; BMI, body mass index.